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Acute Adverse Reactions to Gadolinium in CMR
“Gadol” News!*
Natalie Bello, MD,† Warren J. Manning, MD†‡
Boston, MassachusettsD
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TIn 1794, Johan Gadolin, a Finnish scientist, isolated a
new rare earth metal from a black, heavy mineral
found at a quarry on an island near Stockholm.
Originally named ytterbia, in honor of the nearby
village, the substance soon acquired the name gado-
linite in honor of Johan, and subsequently gadolinium.
Gadolin’s surname, the Hebrew word for “great,” was
chosen from the Bible by his grandfather, a Lutheran
minister (1). Although the paramagnetic properties of
gadolinium have proven it to be a “great” discovery for
biomedical imaging, free gadolinium is highly toxic
See page 1171
and insoluble in water. As such, it must be chelated
for clinical use, with macrocyclic chelates being
more stable than linear chelates. Both variants are
excreted unchanged in the urine. Despite its renal
clearance, for over a decade, gadolinium was the
preferred angiographic contrast agent for patients
with severe renal dysfunction (2–4). That changed
when gadolinium administration was linked to
nephrogenic sclerosing fibrosis, a debilitating and
sometimes fatal, multisystem fibrosing disorder
seen only in patients with severe acute and chronic
renal failure. This association led the U.S. Food and
Drug Administration to issue a black box warning
for gadolinium compounds in 2006 (5).
For over a decade, gadolinium-based contrast
agents have been approved by the U.S. Food and
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contents of this paper to disclose.rug Administration for use with magnetic resonance
maging to visualize lesions with abnormal vascularity
n the brain and associated tissues, head and neck, and
ody (6), with an estimated 45 million doses ad-
inistered in 101 countries (7). Despite obvious
assage of the agent through the heart during intra-
enous administration for approved indications,
adolinium-based contrast agents remain unapproved
or cardiac applications. Today, there is widespread
off-label” use of gadolinium in cardiac magnetic
esonance (CMR), primarily with first-pass myocar-
ial rest and stress perfusion and late gadolinium
nhancement to identify fibrosis and inflammation
7). At our institution, the vast majority (85%) of
MR studies include gadolinium contrast. Even
hough the majority of CMR studies in the literature
ocus on the diagnostic or prognostic utility of en-
ancement following gadolinium administration, little
s known regarding its safety profile when used in this
anner.
In this issue of iJACC, Bruder et al. (8) partially
ddress the deficit in our knowledge regarding acute
oxicity of gadolinium CMR. These investigators
xamined the EuroCMR (European Cardiovascular
agnetic Resonance) registry, a voluntary registry
ataset of over 19,000 clinical CMR studies per-
ormed at 45 European institutions from April 2007
o March 2011. As has been our experience, the vast
ajority (90%) of CMR studies employed gadolin-
um. The 3 leading indications for CMR, comprising
early 80% of studies, were: 1) evaluation of cardio-
yopathy; 2) risk stratification of coronary artery
isease (CAD); and 3) viability assessment (9). De-
pite nearly 18,000 doses, only 30 (0.17%) acute
dverse reactions were reported (Table 1), all of which
ere classified as mild, with an incidence of 0.06%
gadoteridol and gadodiamid) to 0.47% (gadobenat).
he most common acute adverse reactions were rash/
ives, nausea, and anxiety. No moderate or severe
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1178reactions were reported; although some might con-
sider rash/hives as a “moderate” reaction, Bruder et al.
(8) used the American College of Radiology classifi-
ation system of severity and manifestations of adverse
eactions to contrast media (10). An interesting find-
ng was the variability in event rates among indications
or CMR—with patients being risk stratified for
AD having the lowest acute reaction rate (0.10%) as
ompared with a 0.42% acute adverse reaction rate in
iability studies performed in patients with known
AD. The reason for this disparity likely has no
eaningful clinical importance, but has also been
oted in patients given iodinated contrast (10).
As might be expected, because the doses and route
f administration are similar to that employed with
adolinium magnetic resonance imaging of other parts
f the body, the very low acute event rate is within the
.07% to 2.4% acute event rate noted in the general
agnetic resonance literature, with comparable events
ncluding headache, nausea, and coldness at the injec-
ion site (7,10). Moderate and severe reactions are
xceedingly rare. One series of over 687,000 doses
eported only 5 severe reactions (1 of 137,000)
ncluding periorbital edema, severe chest tightness,
ongue swelling, and respiratory distress (11). The
bsence of these toxicities in only 18,000 doses is thus
ot surprising.
We applaud the European Society of Cardiology
ardiac MR Working Group’s foresight in creating
he EuroCMR registry, with internal review and
uditing processes for all centers that perform CMR
n an effort to ensure homogeneity and honesty in
eporting. As highlighted by the investigators, registry
ata are inferior to a prospective randomized trial, but
re more reflective of “real-world” experience than the
ighly selected population of a randomized controlled
rial. The mean dose of gadolinium was 25.6 ml
0.128 mmol/kg) with a range of 0.012 to 0.3 mmol/
Table 1. Reported Side Effects
Nausea
Vomiting
Warmth
Headache
Dizziness
Altered taste
Itching
Flushing
Chills
Sweats
Rash/hives
Swelling of eyes/facew
Anxietyg. Although no relationship between the dose ad-
inistered and acute reactions was noted, data were
ot collected regarding the administration rate, which
ay have an impact on acute toxicity. Importantly, left
nknown are data regarding intermediate- and long-
erm toxicity of gadolinium-based contrast agents in
he cardiac population. By their definition, acute
eactions are those that occur within 60 min of
ontrast administration. Intermediate complications,
uch as thrombophlebitis or delayed allergic reactions,
re also important to track. Unfortunately, the Euro-
MR registry does not mandate intermediate or late
ollow-up for all patients (only for patients enrolled in
pecific CAD and hypertrophic cardiomyopathy pro-
ocols), and long-term complications, such as neph-
ogenic sclerosing fibrosis, are also potentially missed
Table 2) (12). Just as a different event rate was noted
etween patients being screened for CAD and pa-
ients with known CAD, a similar discrepancy could
xist for other complications such as nephrogenic
clerosing fibrosis despite rigorous monitoring of renal
unction, which would be important to track.
While these data confirm the expected safety profile
or the use of gadolinium contrast in CMR based on
adiology applications, they can also be seen as a call
or the creation of a CMR registry in the United
tates or an expanded “worldwide” CMR registry,
erhaps under the umbrella of the Society for Cardio-
ascular Magnetic Resonance. Such an effort would
nable monitoring of indications for CMR, use of and
eactions to contrast agents, as well as adherence to
ppropriateness criteria. The registry may also serve as
platform for cost-effective analyses of the down-
tream testing impact of CMR. In an era of an
ncreased awareness of the rising cost of health care
nd diminishing reimbursement, we should be proac-
ive and use such a registry to track these areas in an
ffort to provide “gadolin” care to our patients.
Reprint requests and correspondence: Dr. Warren J. Man-
ing, Beth Israel Deaconess Medical Center, 330 Brook-
ine Avenue, Boston, Massachusetts 02215. E-mail:
Table 2. EuroCMR Electronic Case Record Form to
Report Complications
Major complications: death, ventricular ﬁbrillation, sustained
ventricular tachycardia, cardiac arrest, allergic shock
Minor complications: allergy to contrast agent (other than shock),
angina pectoris, dyspnea, nonsustained ventricular tachycardia,
paroxysmal atrial ﬁbrillation, severe increase in blood pressure
with dobutamine stress, severe decrease in systolic blood
pressure with dobutamine stress, bronchospasm with adenosine
perfusion, second- or third-degree atrioventricular block, nausea,
local complications at the intravenous infusion site,
claustrophobiamanning@bidmc.harvard.edu.
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